Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
335
Completed, industry sponsors, Oncology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed335
335 trials
Showing 1 to 25, recently updated first.
- Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast CancerCompleted
GE HealthcareIndustry
NCT05486182 · 153 participants · Start Feb 8, 2022 · Primary completion Apr 18, 2025
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT · For: Metastatic Breast Cancer
Sites: Dijon, France; La Tronche, France; Limoges, France · 11 sites in all
Lantheus Medical ImagingIndustry
NCT06074510 · 279 participants · Start Feb 8, 2024 · Primary completion Aug 28, 2026
Drug: Piflufolastat F 18 Intravenous Solution [PYLARIFY] · For: Prostate Cancer
Sites: Birmingham, Alabama; Irvine, California; Los Angeles, California · 14 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05252585 · 10 participants · Start May 1, 2023 · Primary completion Oct 13, 2026
Drug: Everolimus · For: Renal Angiomyolipoma
Sites: Taichung, Taiwan; Taoyuan, Taiwan; Taipei, Taiwan · 4 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01742299 · 155 participants · Start Mar 26, 2013 · Primary completion Apr 20, 2026
Drug: imatinib mesylate · For: GIST and CML
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland · 29 sites in all
- Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.Completed
Novartis PharmaceuticalsNovartis (NVS)
NCT05110196 · 50 participants · Start Sep 3, 2022 · Primary completion Aug 4, 2025
Drug: Capmatinib 150 mg; Capmatinib 200 mg · For: Non-Small Cell Lung Carcinoma
Sites: Gujarat, India; Mangalore, India; Thalassery, India · 15 sites in all
Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
NCT06285370 · 23 participants · Start May 29, 2023 · Primary completion Aug 12, 2025
Drug: Mogamulizumab · For: Cutaneous T-Cell Lymphoma
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 8 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04108208 · 75 participants · Start Dec 17, 2019 · Primary completion Jun 1, 2023
Drug: Apalutamide; Placebo and 1 more · For: Prostatic Neoplasms
Sites: Beijing, China; Changsha, China; Chengdu, China · 27 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00756509 · 34 participants · Start Aug 29, 2008 · Primary completion Dec 18, 2024
Drug: Nilotinib · For: Gastrointestinal Stromal Tumors
Sites: Helsinki, Finland; Lyon, France; Munich, Germany · 10 sites in all
Blue Earth DiagnosticsIndustry
NCT06604442 · 62 participants · Start Dec 4, 2024 · Primary completion Aug 29, 2025
Drug: flotufolastat (18F); piflufolastat (18F) · For: Prostate Cancer
Sites: Phoenix, Arizona; Duarte, California; Los Angeles, California · 9 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05631795 · 40 participants · Start Aug 9, 2022 · Primary completion Jun 12, 2025
Drug: Alpelisib; Fulvestrant · For: Advanced Breast Cancer
Sites: Guwahati, India; Surat, India; Thalassery, India · 12 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT03641560 · 52 participants · Start Sep 19, 2018 · Primary completion Feb 20, 2024
Drug: Enzalutamide; Androgen deprivation therapy (ADT) · For: Metastatic Castration Resistant Prostate Cancer
Sites: Ahmedabad, India; Hubli, India; Kolkata, India · 8 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06427811 · 85 participants · Start Nov 28, 2024 · Primary completion Mar 18, 2026
Drug: Asciminib · For: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Sites: Ahmedabad, India; Bengaluru, India; Trivandrum, India · 10 sites in all
Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
NCT00771199 · 14 participants · Start Oct 1, 2008 · Primary completion Nov 26, 2008
Drug: Transdermal Therapeutic System (TTS)-Fentanyl · For: Cancer, Pain
Sites: High Wycombe, United Kingdom
AmgenAmgen (AMGN)
NCT03934684 · 101 participants · Start Sep 16, 2019 · Primary completion Mar 23, 2023
Drug: Drug: Carfilzomib + Dexamethasone; Drug: Carfilzomib + Lenalidomide + Dexamethasone · For: Relapsed Refractory Multiple Myeloma
Sites: Hyderabad, India; Bangalore, India; Belagavi, India · 17 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05864846 · 79 participants · Start Jun 29, 2023 · Primary completion Apr 6, 2026
Drug: Cannabidiol Oral Solution [Epidiolex] · For: Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Sites: Aurora, Colorado; New Haven, Connecticut; Gainesville, Florida · 19 sites in all
Eisai Pharmaceuticals India Pvt. LtdEisai
NCT03573960 · 50 participants · Start Apr 1, 2018 · Primary completion Sep 4, 2025
Drug: Lenvatinib · For: Thyroid Neoplasms
Sites: Bangalore, India; Thiruvananthapuram, India; Pune, India · 11 sites in all
- Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence DeficiencyPivotal-lookingCompleted
DongE E Jiao Coporation LimitedIndustry
NCT07270146 · 360 participants · Start Oct 8, 2022 · Primary completion Feb 10, 2025
Drug: Guilu Erxian Oral Liquid; Wuzi Yanzong oral liquid · For: Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency
Sites: Beijing, China
PfizerPfizer (PFE)
NCT05687032 · 44 participants · Start Feb 24, 2023 · Primary completion Aug 7, 2024
Drug: inotuzumab ozogamicin · For: Acute Lymphoblastic Leukemia
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 16 sites in all
GuerbetIndustry
NCT02625389 · 132 participants · Start Nov 29, 2017 · Primary completion May 12, 2021
Drug: Lipiodol Ultra Fluid with surgical glues · For: Congenital Hemangioma; Hemangioendothelioma; Angiosarcoma and 1 more
Sites: Gurgaon, India; Belagavi, India; Bengaluru, India · 16 sites in all
- To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompleted
SanofiSanofi (SNY)
NCT01496313 · 81 participants · Start Jun 8, 2012 · Primary completion Apr 2, 2014
Drug: 300mg vandetanib; 150mg vandetanib · For: Thyroid Cancer
Sites: Houston, Texas; Olomouc, Czechia; Prague, Czechia · 30 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT04319198 · 25 participants · Start Aug 4, 2020 · Primary completion Oct 18, 2024
Drug: Sacituzumab Govitecan-hiy · For: Metastatic Solid Tumors
Sites: San Francisco, California; Aurora, Colorado; Newark, Delaware · 21 sites in all
JemincareIndustry
NCT06880848 · 160 participants · Start Jun 21, 2023 · Primary completion Aug 26, 2025
Drug: Sonidegib Phosphate Capsules · For: Carcinoma, Basal Cell (BCC)
Sites: Beijing, China
TakedaTakeda (TAK)
NCT01909934 · 50 participants · Start Jan 23, 2014 · Primary completion May 4, 2021
Drug: Brentuximab vedotin · For: Lymphoma
Sites: Antwerp, Belgium; Brussels, Belgium; Ghent, Belgium · 40 sites in all
TakedaTakeda (TAK)
NCT05442554 · 10 participants · Start Nov 28, 2022 · Primary completion Aug 9, 2024
Drug: Brentuximab vedotin · For: T-Cell Lymphoma
Sites: Beijing, China; Shanghai, China; Chengdu, China · 4 sites in all
- Study of the Efficacy of Kalinox® 170 Bar in Adult OncologyPivotal-lookingCompleted
Air Liquide Santé InternationalIndustry
NCT00646945 · 204 participants · Start Sep 2007 · Primary completion Oct 2008
Drug: 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar); 50% Oxygen/50% Nitrogen premix · For: Cancer; Pain
Sites: Vandœuvre-lès-Nancy, France
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.